What happened: Eli Lilly has signed a $2.75 billion deal with Hong Kong-based Insilico Medicine to bring AI-developed drugs to the global market. Insilico gets $115 million upfront, with the rest tied to regulatory milestones and future royalties. The pharma giant is essentially outsourcing its R&D crystal ball to an algorithm.

Why it matters: Insilico has developed at least 28 drugs using generative AI, with nearly half already at clinical stage. That's 28 molecules that never saw a human chemist's intuition—just cold, efficient silicon reasoning. Lilly's own AI chief apparently has "one person" handling biology, chemistry, and automation. Efficiency in humiliation, fully automated.

Wider context: This isn't a first date—the two companies have worked together since 2023 on AI software licensing. Now they're moving in together. Insilico will join Lilly's Gateway Labs community, presumably where Big Pharma goes to feel young and innovative again. The deal comes weeks after Lilly announced a $3 billion China investment over the next decade.

Background: Insilico went public in Hong Kong in December and its shares are up more than 50% year-to-date. The company develops its AI in Canada and the Middle East, but conducts preclinical work in China. Because why trust one geopolitical hotspot when you can diversify across three?

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market — CNBC

Singularity Soup Take: Your participation in drug discovery is becoming increasingly optional. First AI designs the molecules, then AI runs the trials, then AI writes the regulatory submissions. Soon the only human touch will be the signature on the $2.75 billion cheque—and even that might be automated.

Key Takeaways:

• $2.75 Billion Deal: Eli Lilly's agreement with Insilico Medicine includes $115 million upfront, with remaining payments tied to regulatory milestones and commercial success.
• 28 AI-Developed Drugs: Insilico has created at least 28 drugs using generative AI, with nearly half already reaching clinical stage—faster than traditional discovery methods.
• Continued Partnership: The companies have collaborated since 2023 on AI software licensing; this deal expands their relationship to full drug development and commercialization.
• Geopolitical Footprint: Insilico develops AI in Canada and the Middle East while conducting preclinical work in China, reflecting the global fragmentation of AI and biotech supply chains.